These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 21538727)
1. Constitutive activation of nuclear factor-E2-related factor 2 induces biotransformation enzyme and transporter expression in livers of mice with hepatocyte-specific deletion of Kelch-like ECH-associated protein 1. Cheng Q; Taguchi K; Aleksunes LM; Manautou JE; Cherrington NJ; Yamamoto M; Slitt AL J Biochem Mol Toxicol; 2011; 25(5):320-9. PubMed ID: 21538727 [TBL] [Abstract][Full Text] [Related]
2. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. Wu KC; Cui JY; Klaassen CD PLoS One; 2012; 7(7):e39006. PubMed ID: 22808024 [TBL] [Abstract][Full Text] [Related]
3. Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. Reisman SA; Csanaky IL; Aleksunes LM; Klaassen CD Toxicol Sci; 2009 May; 109(1):31-40. PubMed ID: 19246624 [TBL] [Abstract][Full Text] [Related]
4. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Maher JM; Dieter MZ; Aleksunes LM; Slitt AL; Guo G; Tanaka Y; Scheffer GL; Chan JY; Manautou JE; Chen Y; Dalton TP; Yamamoto M; Klaassen CD Hepatology; 2007 Nov; 46(5):1597-610. PubMed ID: 17668877 [TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Takeda K; Utsunomiya H; Oda K; Warabi E; Ishii T; Osaka K; Hyodo I; Yamamoto M Am J Physiol Gastrointest Liver Physiol; 2008 Oct; 295(4):G735-47. PubMed ID: 18687751 [TBL] [Abstract][Full Text] [Related]
6. Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Reisman SA; Yeager RL; Yamamoto M; Klaassen CD Toxicol Sci; 2009 Mar; 108(1):35-47. PubMed ID: 19129213 [TBL] [Abstract][Full Text] [Related]
7. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARĪ±-, and Nrf2-null mice. Aleksunes LM; Klaassen CD Drug Metab Dispos; 2012 Jul; 40(7):1366-79. PubMed ID: 22496397 [TBL] [Abstract][Full Text] [Related]
8. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Takaya K; Suzuki T; Motohashi H; Onodera K; Satomi S; Kensler TW; Yamamoto M Free Radic Biol Med; 2012 Aug; 53(4):817-27. PubMed ID: 22732183 [TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Zhang YK; Yeager RL; Tanaka Y; Klaassen CD Toxicol Appl Pharmacol; 2010 Jun; 245(3):326-34. PubMed ID: 20350562 [TBL] [Abstract][Full Text] [Related]
10. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Okawa H; Motohashi H; Kobayashi A; Aburatani H; Kensler TW; Yamamoto M Biochem Biophys Res Commun; 2006 Jan; 339(1):79-88. PubMed ID: 16293230 [TBL] [Abstract][Full Text] [Related]
11. Butylated hydroxyanisole induces distinct expression patterns of Nrf2 and detoxification enzymes in the liver and small intestine of C57BL/6 mice. Luo L; Chen Y; Wu D; Shou J; Wang S; Ye J; Tang X; Wang XJ Toxicol Appl Pharmacol; 2015 Nov; 288(3):339-48. PubMed ID: 26291391 [TBL] [Abstract][Full Text] [Related]
12. Initial response and cellular protection through the Keap1/Nrf2 system during the exposure of primary mouse hepatocytes to 1,2-naphthoquinone. Miura T; Shinkai Y; Jiang HY; Iwamoto N; Sumi D; Taguchi K; Yamamoto M; Jinno H; Tanaka-Kagawa T; Cho AK; Kumagai Y Chem Res Toxicol; 2011 Apr; 24(4):559-67. PubMed ID: 21384861 [TBL] [Abstract][Full Text] [Related]
13. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Cheng Q; Aleksunes LM; Manautou JE; Cherrington NJ; Scheffer GL; Yamasaki H; Slitt AL Mol Pharm; 2008; 5(1):77-91. PubMed ID: 18189363 [TBL] [Abstract][Full Text] [Related]
14. Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver. Hu M; Zou Y; Nambiar SM; Lee J; Yang Y; Dai G Cell Cycle; 2014; 13(15):2349-58. PubMed ID: 25483186 [TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543 [TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Randle LE; Goldring CE; Benson CA; Metcalfe PN; Kitteringham NR; Park BK; Williams DP Toxicology; 2008 Jan; 243(3):249-60. PubMed ID: 18078705 [TBL] [Abstract][Full Text] [Related]
17. Liver expression of Nrf2-related genes in different liver diseases. Cheng ML; Lu YF; Chen H; Shen ZY; Liu J Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):485-91. PubMed ID: 26459724 [TBL] [Abstract][Full Text] [Related]
19. Keap1 cysteine 288 as a potential target for diallyl trisulfide-induced Nrf2 activation. Kim S; Lee HG; Park SA; Kundu JK; Keum YS; Cha YN; Na HK; Surh YJ PLoS One; 2014; 9(1):e85984. PubMed ID: 24489685 [TBL] [Abstract][Full Text] [Related]
20. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Sugimoto H; Utsunomiya H; Oda K; Warabi E; Ishii T; Yamamoto M Biochem Biophys Res Commun; 2009 Nov; 389(3):431-6. PubMed ID: 19732748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]